Endonovo Therapeutics, Inc. announced an agreement with NAMSA – a leading Global Contract Research Organization (CRO) and medical device reimbursement specialist – as strategic advisors to develop in-patient and out-patient medical reimbursement strategies for Endonovo's PEMF (Pulsed Electro-Magnetic Field) product SofPulse®. NAMSA was founded in 1967 as a scientific research company and later transitioned into a Global CRO and Medtech (Medical Technologies) reimbursement specialist. NAMSA offers a full continuum of reimbursement services for medical technologies.

Their reimbursement consultants provide: payer relations, medical policy research, coverage advocacy, Healthcare Common Procedure Coding System (HCPCS), Current Procedural Terminology (CPT) code analysis/applications and health economic analysis. NAMSA provides strategic guidance and tactical support to fast-track medical device commercialization and to make an immediate impact on patient healthcare worldwide. NAMSA's services have grown to include regulatory, reimbursement and quality consulting as well as clinical research.

These additions have helped NAMSA to become the pre-eminent 100% medical device-focused Global CRO that offers proven strategic solutions throughout the full development continuum. NAMSA is the only US FDA ASCA accredited medical device biocompatibility laboratory in the world. This allows medical device sponsors to fast-track commercialization efforts, while achieving time and cost efficiencies in every major market of the world.